Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographic, clinical, and serological characteristics of the patients and controls

From: CD4 T lymphocyte autophagy is upregulated in the salivary glands of primary Sjögren’s syndrome patients and correlates with focus score and disease activity

  Primary Sjögren’s syndrome (n = 30) Nonspecific chronic sialoadenitis (n = 20) Healthy controls (n = 30)
Age, mean years (range) 59.3 (32–75) 55 (29–77) 50 (25–68)
Sex, female/male 29/1 18/2 25/5
Disease duration, mean years (range) 5.4 (1–26)
Xerophtalmia, n (%) 29 (96.6) 12 (60) 0
Xerostomia, n (%) 27 (90) 12 (60) 0
Parotid enlargement, n (%) 11 (36.6) 0 0
Arthralgia/arthritis, n (%) 23 (76.6) 10 (50) 0
Cryoglobulinemia, n (%) 1 (3.3) 0 0
Raynaud’s phenomenon, n (%) 6 (20) 12 (60) 0
Pulmonary involvement, n (%) 1 (3.3) 0 0
Myositis, n (%) 2 (6.6) 0 0
Pancreatic involvement, n (%) 1 (3.3) 0 0
Lymphoma, n (%) 1 (3.3) 0 0
Antinuclear antibodies, n (%) 28 (93.3) 5 (25) 0
Anti-SSA/Ro, n (%) 17 (56.6) 0 0
Anti-SSB/La, n (%) 13 (43.3) 0 0
Rheumatoid factor, n (%) 11 (36.6) 2 (10) 0
IL21, pg/mL median (range) 292 (164–839) 310 (150–999) 301 (177–777)
IL23, pg/mL median (range) 2113 (1838–3567) 2050 (1200–5600) 1913 (1361–10936)
CSS, n (%) 6 (20)
Hydroxychloroquine, n (%) 16 (53.3)
SSDAI, median (range) 3 (0–8)
ESSDAI, median (range) 5.1 (0–24)
SSDDI, median (range) 1.7 (1–7)
  1. ESSDAI EULAR Sjögren’s syndrome disease activity index, SSDAI Sjögren’s syndrome disease activity index, SSDDI Sjögren’s syndrome disease damage index